ABCSG 67N / CAROLEEN study: First Patient Enrolled
30.10.2025The ABCSG is pleased to announce that the first patient from Austria has been enrolled in the ABCSG 67N / CAROLEEN at Sanatorium Hera under the leadership of PI Yelena Devyatko.
We warmly congratulate PI Yelena Devyatko and the dedicated team in Sanatorium Hera on this important first milestone.
ABCSG 67N / CAROLEEN is a non-interventional study (NIS) investigating Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of patients with HR+/HER2- early breast cancer at high risk of recurrence. The aim of the study is to evaluate the effectiveness and safety profile of the treatment as well as therapy compliance and patients’ quality of life.
The NIS is being conducted in Austria led by Principal Investigator Univ.-Prof. Dr. Christian Singer (Medical University of Vienna). A total of 3,250 patients are planned to be enrolled of which approximately 300 patients will be enrolled in Austria.
More posts on the topic:
ABCSG 67N
Share on